2. Academic Validation
  3. Avapritinib efficacy in primary hepatic neuroendocrine carcinoma with elevated PDGFRA expression: Insights from a PDX model study

Avapritinib efficacy in primary hepatic neuroendocrine carcinoma with elevated PDGFRA expression: Insights from a PDX model study

  • Biochem Biophys Res Commun. 2024 Aug 6:736:150504. doi: 10.1016/j.bbrc.2024.150504.
Yang Zhou 1,  Xiang-Lin Song 2,  Luo-Bin Guo 3,  Xiao-Ruo Yu 4,  Ying-Chao Wang 5
Affiliations

Affiliations

  • 1 Biobank, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China; The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China. Electronic address: 18559897770@163.com.
  • 2 Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China. Electronic address: 766016689@qq.com.
  • 3 The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China; Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China. Electronic address: 362348102@qq.com.
  • 4 Department of Nursing, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China. Electronic address: 1647465090@qq.com.
  • 5 Biobank, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China; The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China; Fujian Province Liver Disease Research Center, Fuzhou, China. Electronic address: yingchaowang@live.com.
PMID: 39121673 DOI: 10.1016/j.bbrc.2024.150504
Abstract

Background & aims: Primary Hepatic Neuroendocrine Carcinoma (PHNEC) is a rare and aggressive tumor with high recurrence rates. Surgical resection remains the only therapeutic strategy. The effectiveness of tyrosine kinase inhibitors (TKIs) for PHNEC remains unclear due to limited research.

Methods: We employed immunohistochemical staining to diagnose PHNEC and assess the expression of eight tyrosine kinase receptors in tumor tissues, including VEGFRs, PDGFRA, EGFR, FGFRs et al. A patient-derived xenograft (PDX) model was established using PHNEC tumor tissues to test the efficacy of TKIs. PDX mice bearing tumors were treated with Avapritinib, an FDA-approved PDGFRA-targeting drug, at a daily oral dose of 10 mg/kg for 2 weeks.

Results: Pathological analysis confirmed the diagnosis of PHNEC with positive expression of Neural cell adhesion molecule (NCAM/CD56), Synaptophysin (Syn), and Somatostatin Receptor 2 (SSTR-2), and negative expression of Hep (Hepatocyte Paraffin 1), a biomarker for Hepatocellular carcinoma. Notably, PDGFRA was significantly overexpressed in PHNEC tumor tissues compared to other tyrosine kinases. Avapritinib treatment significantly reduced tumor growth in PDX mice by 73.9 % (p = 0.008). Additionally, Avapritinib treatment led to a marked decrease in PDGFRA and Ki-67 expression, suggesting that it inhibits tumor cell proliferation by suppressing PDGFRA.

Conclusion: Our findings suggest that PDGFRA is a potential therapeutic target for PHNEC, and its inhibition with Avapritinib may offer clinical benefits to patients with this rare malignancy.

Keywords

Avapritinib; Patient derived xenograft; Platelet-derived growth factor receptor alpha; Primary hepatic neuroendocrine carcinoma; Surgical resection; Tyrosine kinase receptors.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z